Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ, Rudek MA, Smith BD.

Leukemia. 2010 Aug;24(8):1437-44. doi: 10.1038/leu.2010.132. Epub 2010 Jun 10.

PMID:
20535150
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE.

Haematologica. 2011 Jan;96(1):62-8. doi: 10.3324/haematol.2010.030452. Epub 2010 Oct 15.

PMID:
20952518
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1874-7. doi: 10.1016/j.bbmt.2011.07.011. Epub 2011 Jul 20.

PMID:
21767516
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD.

J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18.

PMID:
21768474
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A.

Blood. 2009 Jun 25;113(26):6567-71. doi: 10.1182/blood-2009-03-208298. Epub 2009 Apr 23.

PMID:
19389879
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.

PMID:
24002496
[PubMed - indexed for MEDLINE]
8.

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.

Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4.

PMID:
17205056
[PubMed - indexed for MEDLINE]
9.

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

Kancha RK, Grundler R, Peschel C, Duyster J.

Exp Hematol. 2007 Oct;35(10):1522-6.

PMID:
17889720
[PubMed - indexed for MEDLINE]
10.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A.

Leukemia. 2012 Nov;26(11):2353-9. doi: 10.1038/leu.2012.105. Epub 2012 Apr 16.

PMID:
22504140
[PubMed - indexed for MEDLINE]
11.

A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.

Fesler MJ, Richart JM, Petruska PJ.

Leuk Res. 2010 Oct;34(10):e268-9. doi: 10.1016/j.leukres.2010.03.046. Epub 2010 Apr 24. No abstract available.

PMID:
20417967
[PubMed - indexed for MEDLINE]
12.

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, Small D, Burnett A, Levis M.

Blood. 2011 Mar 24;117(12):3286-93. doi: 10.1182/blood-2010-01-266742. Epub 2011 Jan 24.

PMID:
21263155
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

PMID:
23969938
[PubMed - indexed for MEDLINE]
14.

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M.

Blood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.

PMID:
23613521
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.

Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.

PMID:
24046014
[PubMed - indexed for MEDLINE]
16.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY.

Blood. 2012 May 31;119(22):5133-43. doi: 10.1182/blood-2011-06-363960. Epub 2012 Feb 24.

PMID:
22368270
[PubMed - indexed for MEDLINE]
Free Article
17.

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.

Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L.

Leuk Lymphoma. 2010 Feb;51(2):252-60. doi: 10.3109/10428190903585286.

PMID:
20109071
[PubMed - indexed for MEDLINE]
18.

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM.

Clin Cancer Res. 2012 Nov 1;18(21):6011-22. doi: 10.1158/1078-0432.CCR-11-3284. Epub 2012 Sep 7.

PMID:
22962440
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6. doi: 10.1016/j.clml.2011.06.007.

PMID:
21816375
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.

Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, Dudley M, Glaser K, McKeegan E, Albert DH, Li X, Pradhan R, Stock W.

Leuk Lymphoma. 2012 Aug;53(8):1543-51. doi: 10.3109/10428194.2012.660631. Epub 2012 Mar 1.

PMID:
22280537
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk